Instituts de recherche en santé du Canada
570 556 captures · dernière capture : 3 mai 2026
Page d’accueil :https://cihr-irsc.gc.ca/f/193.html
Le français est une traduction alpha automatisée. Pour le texte officiel, consultez la version anglaise.
Explorateur d’archives
Parcourir et rechercher des captures
Note importante
Parcourez et recherchez des captures historiques. Ceci est une archive — pas des directives actuelles ni un avis médical. Le contenu archivé peut être incomplet, périmé ou remplacé. Pour des recommandations à jour, consultez toujours le site officiel de la source.
Pour plus de contexte sur la couverture et les méthodes de capture, voir Méthodes et couverture.
Parcourir les sites archivés
Santé Canada
386 223 captures · dernière capture : 14 avr. 2026
Page d’accueil :https://www.canada.ca/fr/sante-canada.html
Agence de la santé publique du Canada
243 880 captures · dernière capture : 28 avr. 2026
Page d’accueil :https://www.canada.ca/fr/sante-publique.html
Good manufacturing practices guide for natural health products (GUI-0158): Overview, about NHP quality systems Overview, about NHP quality systems NHP GMP guidance, sections 43 to 47 NHP GMP guidance, sections 48 to 50 NHP GMP guidance, section 51 NHP GMP guidance, sections 52 to…
Notice of amendment: Addition of melatonin to the Prescription Drug List September 9, 2025 Our file number: 25-105825-747 The purpose of this Notice of Amendment is to announce the addition of "melatonin or its salts" to the human use part of the Prescription Drug List (PDL).…
Closed consultation: Adding melatonin for sleep-related use in the pediatric population to the Prescription Drug List Current status: Closed This consultation ran from September 16, 2025 to December 30, 2025. The purpose of this consultation was to communicate to industry,…
Closed consultation: Draft guidance on the plain language labelling regulations for prescription drugs Current status: Closed This consultation ran from September 25, 2025 to November 7, 2025. Health Canada sought feedback on proposed revisions to the Questions and Answers: Plain…
Qualifying notice for Amtagvi (293019) Biologic and Radiopharmaceutical Drugs Directorate 100 Eglantine Driveway LCDC Building Tunney's Pasture, A.L. 0601C Ottawa ON K1A 0K9 Dossier ID: e279570 Control number: 293019 Iovance Biotherapeutics, Inc. c/o [employee name removed]…
Health Canada updates guidance on management of drug submissions and applications: Notice October 1, 2025 Health Canada has updated the 2022 version of the Guidance on management of drug submissions and applications . The changes to the guidance take effect immediately and will…
Health Canada implementation of International Council for Harmonisation Q12 Technical and regulatory considerations for pharmaceutical product lifecycle management and Q14 Analytical procedure development: Notice January 12, 2026 Our file number: 25-105890 – 674 As a standing…
What we heard: Draft guidance on co-packaged drug products On this page Introduction Stakeholder engagement Key themes Summary of feedback Next steps Contact us Introduction Health Canada published the Draft guidance on co-packaged drug products for public consultation on March…
Qualifying notice for Enhertu (288114) Biologic and Radiopharmaceutical Drugs Directorate 100 Eglantine Driveway LCDC Building Tunney’s Pasture, A.L. 0601C Ottawa ON K1A 0K9 Dossier ID: e231047 Control number: 288114 [employee name removed] [employee title removed] Astra Zeneca…
Notice: Multiple additions to the Prescription Drug List (PDL) [2025-10-30] October 30, 2025 Our file number: 25-107098-682 The purpose of this Notice of Amendment is to announce the addition of belantamab mafodotin, bulevirtide, delgocitinib, deutivacaftor, elinzanetant,…
Page 4294 sur 6399Affichage de 42931 à 42940 sur 63986
Version préliminaire : la couverture et les fonctionnalités sont encore en expansion.
